Dm Disease-A-MonthPub Date : 2024-06-22DOI: 10.1016/j.disamonth.2024.101780
{"title":"Cardiovascular complications during pregnancy: Advancing cardio-obstetrics","authors":"","doi":"10.1016/j.disamonth.2024.101780","DOIUrl":"10.1016/j.disamonth.2024.101780","url":null,"abstract":"<div><p>As the incidence of cardiovascular diseases (CVDs) continues to rise among women of childbearing age, the pregnant population with pre-existing heart conditions presents a complex and heterogeneous profile. These women face varying degrees of risk concerning maternal cardiovascular, obstetric, and fetal complications. Effectively managing adverse cardiovascular events during pregnancy presents substantial clinical challenges. The uncertainties surrounding diagnostic and therapeutic approaches create a dynamic landscape with potential implications for maternal and fetal health. Cardio-obstetrics has become increasingly recognized as a vital multidisciplinary field necessitating a collaborative approach to managing cardiovascular conditions during pregnancy. In this review, we aim to provide a thorough and up-to-date examination of the existing evidence, offering a comprehensive overview of strategies and considerations in the management of cardiovascular complications during pregnancy. Special emphasis is placed on the safety assessment of diagnostic procedures and the exploration of treatment options designed to prioritize the well-being of the mother and fetus. We also explore the significance of a multidisciplinary cardio-obstetrics team in providing comprehensive care for women of childbearing age with or at risk for CVD.</p></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"70 10","pages":"Article 101780"},"PeriodicalIF":3.8,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011502924001068/pdfft?md5=2c5a8efac69431932bd56b793af16aab&pid=1-s2.0-S0011502924001068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The efficacy and safety of gene therapy approaches in Parkinson's disease: A systematic review","authors":"Chiranjeevee R. Saravanan MBBS , Reem Faiz Hussein Eisa MBBS , Elizabeth Gaviria MD , Amani Algubari MD , Kiran Kishor Chandrasekar MBBS , Pugazhendi Inban MD , Priyadarshi Prajjwal MBBS , Hyma Bamba MBBS , Gurmehar Singh MBBS , Mohammed Dheyaa Marsool Marsool MBChB , Srikanth Gadam MD","doi":"10.1016/j.disamonth.2024.101754","DOIUrl":"10.1016/j.disamonth.2024.101754","url":null,"abstract":"<div><h3>Background</h3><p>Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the brain. Despite existing treatments, there remains an unmet need for therapies that can halt or reverse disease progression. Gene therapy has been tried and tested for a variety of illnesses, including PD. The goal of this systematic review is to assess gene therapy techniques' safety and effectiveness in PD clinical trials.</p></div><div><h3>Methods</h3><p>Online databases PubMed/Medline, and Cochrane were used to screen the studies for this systematic review. The risk of bias of the included studies was assessed using standard tools.</p></div><div><h3>Results</h3><p>Gene therapy can repair damaged dopaminergic neurons from the illness or deal with circuit anomalies in the basal ganglia connected to Parkinson's disease symptoms. Rather than only treating symptoms, this neuroprotective approach alters the illness itself. Medication for gene therapy is currently administered at the patient's bedside. It can hyperactivate specific brain circuits associated with motor dysfunction. PD therapies are developing quickly, and there aren't enough head-to-head trials evaluating the safety and effectiveness of available treatments. When choosing an advanced therapy, patient-specific factors should be considered in addition to the effectiveness and safety of each treatment option.</p></div><div><h3>Conclusion</h3><p>In comparison to conventional therapies, gene therapy may be advantageous for PD. It may minimize side effects, relieve symptoms, and offer dependable dopamine replacement.</p></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"70 7","pages":"Article 101754"},"PeriodicalIF":4.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dm Disease-A-MonthPub Date : 2024-06-01DOI: 10.1016/j.disamonth.2024.101691
Berrin Ergun-Longmire MD, Donald E. Greydanus MD, DrHC (Athens)
{"title":"Ovarian tumors in the pediatric population: An update","authors":"Berrin Ergun-Longmire MD, Donald E. Greydanus MD, DrHC (Athens)","doi":"10.1016/j.disamonth.2024.101691","DOIUrl":"10.1016/j.disamonth.2024.101691","url":null,"abstract":"<div><p>Research reveals that 1% of neoplasms in females under 17 years of age are ovarian neoplasms and though usually benign, malignant tumors may occur in the pediatric age group. This review considers various current concepts of these tumors including the epidemiology, risk factors, clinical presentations, diagnosis, differential diagnosis, and treatment options including the need to provide fertility-sparing surgery as well as their potential impacts on the psychological well-being of children and adolescents.</p><p>We gathered data from the published articles ranging from studies, meta-analyses, retrospective studies, and reviews. We focused on the articles published in English between January 1, 2000, and August 31, 2023. Only a few articles published prior to 2000 were included for historical perspective.</p></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"70 6","pages":"Article 101691"},"PeriodicalIF":4.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139572133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dm Disease-A-MonthPub Date : 2024-06-01DOI: 10.1016/j.disamonth.2024.101690
Jerrold B. Leikin MD (Senior EditorDisease-A-Month)
{"title":"Foreword for: Ovarian tumors in the pediatric population: An update","authors":"Jerrold B. Leikin MD (Senior EditorDisease-A-Month)","doi":"10.1016/j.disamonth.2024.101690","DOIUrl":"10.1016/j.disamonth.2024.101690","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"70 6","pages":"Article 101690"},"PeriodicalIF":4.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139556604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}